A glimmer of hope has emerged for mesothelioma patients, a group facing an incredibly challenging diagnosis. Mesothelioma, often linked to asbestos exposure, is notoriously resistant to treatment, leaving patients with limited options and a bleak outlook. However, a recent breakthrough presented at the European Society for Medical Oncology Congress in Berlin has sparked excitement and renewed optimism.
Vivace Therapeutics, a leading biotech company, unveiled its investigational drug, VT3989, which achieved an impressive 32% objective response rate in patients with treatment-resistant mesothelioma. The results, published in Nature Medicine, revealed that out of 22 evaluated patients, seven experienced a remarkable 30% or more reduction in tumor size, while the tumors of 12 others stabilized.
But here's where it gets even more promising: the 22 mesothelioma patients enrolled in Vivace's study survived without cancer progression for a median of 40 weeks, significantly outperforming the standard-of-care salvage chemotherapy treatment's benchmark of 15 weeks. This remarkable achievement has prompted Vivace to plan a phase 3 registrational study in the first half of 2026.
The study, which enrolled a total of 172 participants, including mesothelioma patients and those with other solid tumors, demonstrated an encouraging safety profile. Only 3.5% of participants discontinued treatment due to adverse events, and most side effects were classified as mild to moderate.
Dr. Timothy Yap, a renowned medical oncologist at MD Anderson Cancer Center and the lead investigator of the phase 1/2 trial, emphasized the potential of VT3989. With mesothelioma presenting unique treatment challenges and limited therapeutic options, the combination of strong efficacy findings and a favorable safety profile makes further studies imperative.
And this is the part most people miss: if approved by the FDA, VE3989 would be the first drug to target the Hippo pathway, which regulates cell growth, migration, and death. Researchers have discovered that many cancer cells, including mesothelioma, exhibit an overactive Hippo pathway. The investigational compound aims to calm this overactive system by inhibiting TEAD transcription factors, which play a crucial role in regulating the Hippo pathway. This mechanism of action could be a game-changer for treating mesothelioma.
For those affected by mesothelioma, this research offers a ray of hope. To learn more about the resources and support available, reach out to the Patient Advocates at Mesothelioma.net at 1-800-692-8608.
Terri Heimann Oppenheimer, the head writer of the Mesothelioma.net news blog, emphasizes the importance of sharing knowledge and stories to empower those impacted by this devastating disease.
